On the label, “maintenance dose” means something narrower than most people asking this question intend: 2.4 mg weekly, the full dose you stay at once titration is done. If you’re asking the other question — whether a lower ongoing dose can hold the weight you’ve already lost, so the choice isn’t full dose forever versus stopping cold — the answer is: no trial has tested it, the mechanism makes it plausible, and clinicians do it case by case anyway.
Why not just stop?
Because the withdrawal data is lopsided. In STEP 4 (Rubino et al., JAMA 2021), participants who switched from semaglutide to placebo at week 20 regained substantially; those who continued kept losing. SURMOUNT-4 (Aronne et al., JAMA 2024) ran the same design with tirzepatide: roughly 14% regained in the year after withdrawal, versus a further 5.5% lost on continued treatment. The mechanism predicts exactly this. GLP-1 receptor agonism quiets appetite circuits in the hypothalamus and hindbrain and slows gastric emptying — while the drug is present. Clear it, and appetite returns. The weight follows.
Stopping outright is still a legitimate choice with its own playbook — we cover it in our guide to stopping a GLP-1.
How thin the lower-dose evidence is
Here is the entire randomized evidence for maintaining on a reduced dose: there isn’t any. STEP 1 (Wilding et al., NEJM 2021, n=1,961) held 2.4 mg for 68 weeks — 14.9% mean loss versus 2.4% on placebo. The withdrawal trials compared full dose against zero. No arm anywhere lost weight at 2.4 mg and then stepped down to 1.0 mg to see whether the loss held. Does a lower dose defend a weight the full dose achieved? We don’t know.
What exists is plausibility. The lower rungs of the ladder — 0.25, 0.5, 1.0, 1.7 mg — are the same molecule at the same receptors, and holding a weight should take less pharmacological pressure than driving it down: the drug’s job shifts from creating a deficit to blunting the rebound in appetite. That is a reasonable hypothesis. Reasonable hypotheses lose in trials all the time.
This is not “microdosing.” Sub-starting-dose regimens are being marketed hard right now, and the claims have outrun the evidence — no trial supports sub-therapeutic dosing for weight loss. A supervised step-down at least stays on doses the STEP safety data covers.
What a step-down looks like in practice
Case by case, because there is no trial protocol to borrow. The titration ladder is the natural frame: it climbs in roughly 4-week steps, and a step-down retraces it. Drop one level, hold, and watch two signals over the following weeks: appetite (is the food noise back?) and the scale. Both quiet: stay, or step down again. Hunger back and weight drifting up: the dose you just left was the answer — step back up.
Two things change the calculus:
- Why you’re on it. In SELECT (Lincoff et al., NEJM 2023, n=17,604 adults with established cardiovascular disease), semaglutide cut major adverse cardiovascular events by 20% in relative terms. That benefit was demonstrated on the trial’s full dosing protocol — nobody has shown it survives a dose reduction. If cardiovascular protection is part of why you’re taking the drug, a step-down trades away its best-evidenced benefit.
- Your history on the way up. If appetite was already loud at 1.0 mg during titration, 1.0 mg is unlikely to hold you on the way down. The doses you’ve lived at are data.
At goal, we hold your effective dose for three months before touching anything. That is not caution for its own sake; it is the window where regain is most likely and least visible.
Then down one rung every 8–12 weeks, watching what the weight does at each stop. The lowest dose that holds you is the destination, and you find it by walking down until the weight tells you to stop. If it drifts up over a month at the new rung, go back one. That is not a failure of the taper, it is the taper working — you found the floor.
The money math
For most people this is a cash decision either way: Medicare Part D is barred by statute from covering drugs for weight loss, and commercial plans often exclude them. Zappy is cash-pay and FSA/HSA eligible; current pricing for compounded semaglutide and tirzepatide is on each treatment page. (Compounded means prepared by LegitScript-verified 503A US pharmacies; compounded preparations themselves are not FDA-approved.)
So price both plans. Maintenance: twelve months at the current rate, indefinitely, for a strategy backed by mechanism and clinical judgment rather than a trial. Stopping: nothing, plus — on the SURMOUNT-4 numbers — a strong likelihood of regaining much of the weight within a year, then paying for a full re-titration, about 16 weeks back to dose, if you restart. One plan costs money; the other, on current evidence, usually costs the result.
Decide it before the refill, not after
If you’re on semaglutide and closing in on a weight you’d be glad to keep, raise the maintenance question one refill early — a planned step-down with scheduled check-ins beats improvising when the last pen runs out. At Zappy, a clinician reviews every case, dose changes included, within 24 hours. And if you’re still working out whether a GLP-1 fits you at all, start with the quiz.
The trial that would settle this — reach goal on 2.4 mg, then randomize to step down or stay — has not been run. Until it is, a lower maintenance dose stays what it is today: a judgment call, made one rung at a time, with your own appetite as the readout.
